Vor Biopharma Inc VOR
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-05 |
| Shares Out. | 54,190,000 |
| Website | vorbio.com/ ↗ |
| Phone | 16176556580 |
| Employees | 76 |
| Net Income | -$219.6M |
| Free Cash Flow | -$150.7M |
| Total Assets | $506.7M |
| Total Liabilities | $657.2M |
| Equity | -$150.4M |
About Vor Biopharma Inc
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Vor Biopharma Inc is a publicly traded company under the ticker symbol VOR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)